Skip to main content
. 2022 Jun 30;23(13):7320. doi: 10.3390/ijms23137320

Figure 5.

Figure 5

Sub-chronic CR4056 treatment has anti-inflammatory effect in 5xFAD mouse brain. (A) Representative images of Iba1 immunostaining in sections from 5xFAD mice after treatment with vehicle or CR4056. (B,C) Quantification of percentage of area covered with Iba1-positive staining in cortex (n = 5–6 per group) and hippocampus (n = 6 per group) of 5xFAD mice. (D,E) Quantification of Iba1-positive cells in cortex and hippocampus of 5xFAD mice, respectively (n = 6 per group). (F) Representative images of CD68-immunohistochemistry in cortex and hippocampus in sections from 5xFAD mice after with vehicle or CR4056. (G,H) Quantification of percentage of area covered and number of CD68-positive cells, respectively, in the hippocampus of 5xFAD mice (n = 5–6 per group). (I,J) Quantification of percentage of area covered and number of CD68-positive cells, respectively in the cortex of 5xFAD mice (n=5–6 per group). (K,L) Measurement of process thickness and length of CD68-positive cells in hippocampus (n = 5–6 per group) and cortex ((M,N) n = 4–6 per group) of 5xFDA mice. (O–T) Quantification of expression of cytokines by ELISA in homogenate from cortex and hippocampus of 5xFAD mice after CR4046 treatment. IL-1β ((O,P), n = 4–7 per group), TNF-α ((Q,R), n = 5–8 per group) and IL-6 ((S,T), n = 7–8 per group). Columns represent mean ± SEM. One-tailed Student’s t-test, * p < 0.05.